Lipid-lowering drugs show benefits in melanoma prevention

Article

Fourteen of 3,304 lovastatin recipients developed melanoma during five years of follow-up, compared to 27 of 3,301 placebo patients

Related Videos
Related Content

Discovering Last Month's Psoriasis Spotlight

October 3rd 2023

The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis

June 12th 2023

Get Ready to Test Your Atopic Dermatitis Knowledge

October 2nd 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

FDA Issues Complete Response Letter for Lebrikizumab

October 2nd 2023

Eczema Resources for Your Patients: Week 1

October 2nd 2023

Discovering Last Month's Psoriasis Spotlight

October 3rd 2023

The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis

June 12th 2023

Get Ready to Test Your Atopic Dermatitis Knowledge

October 2nd 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

FDA Issues Complete Response Letter for Lebrikizumab

October 2nd 2023

Eczema Resources for Your Patients: Week 1

October 2nd 2023

Discovering Last Month's Psoriasis Spotlight

October 3rd 2023

The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis

June 12th 2023

Get Ready to Test Your Atopic Dermatitis Knowledge

October 2nd 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

FDA Issues Complete Response Letter for Lebrikizumab

October 2nd 2023

Eczema Resources for Your Patients: Week 1

October 2nd 2023
© 2023 MJH Life Sciences

All rights reserved.